cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Aclaris Therapeutics Inc
36 own
31 watching
Current Price
$1.21
$-0.01
(-0.82%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
87.09M
52-Week High
52-Week High
11.12000
52-Week Low
52-Week Low
0.59000
Average Volume
Average Volume
0.87M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization87.09M
icon52-Week High11.12000
icon52-Week Low0.59000
iconAverage Volume0.87M
iconDividend Yield--
iconP/E Ratio--
What does the Aclaris Therapeutics Inc do?
Developing a proprietary hydrogen peroxide treatment for common skin lesions.
Read More
How much money does Aclaris Therapeutics Inc make?
News & Events about Aclaris Therapeutics Inc.
Stock Options Channel
10 months ago
Investors eyeing a purchase of Aclaris Therapeutics Inc (ACRS) shares, but tentative about paying the going market price of 9.86/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the February ...
Ticker Report
1 year ago
Aclaris Therapeutics, Inc. (NASDAQ:ACRS Get Rating) Stock analysts at Jefferies Financial Group boosted their FY2025 earnings per share estimates for Aclaris Therapeutics in a note issued to investors on Monday, March 6th. Jefferies Financial Group analyst R. Song now expects that ...
Zolmax
1 year ago
Aclaris Therapeutics (NASDAQ:ACRS Get Rating) had its target price decreased by The Goldman Sachs Group from $25.00 to $21.00 in a report released on Tuesday , Benzinga reports. The Goldman Sachs Group currently has a buy rating on the biotechnology companys stock. Several other research analysts ...
Benzinga
1 year ago
Gainers Unicycive Therapeutics, Inc. (NASDAQ: UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. read more...
Globe Newswire
1 year ago
WAYNE, Pa., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today is providing a corporate outlook for 2023. 2023 is setting up to be an incredibly ...
Frequently Asked Questions
Frequently Asked Questions
What is Aclaris Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Aclaris Therapeutics Inc shares?
plus_minus_icon
How can I buy Aclaris Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Aclaris Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Aclaris Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Aclaris Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Aclaris Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Aclaris Therapeutics Inc?
plus_minus_icon
What percentage is Aclaris Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Aclaris Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.21
$-0.01
(-0.82%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00